Testing SIBP-A17 for advanced solid tumors with HER2
Part of Cancer clinical trials.
This trial tests a new drug called SIBP-A17 for advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a protein called HER2, and the goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have an advanced solid tumor that has not responded to standard treatments or you cannot take them.
- Your tumor expresses a protein called HER2 (either low or high levels tested by a biopsy).
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are in good enough health to walk around and take care of yourself (ECOG 0 or 1).
- You are willing to provide a tumor sample (if in the expansion phase) and use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new drug called SIBP-A13 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for different cancer types, including lung, breast, and head and neck cancers.
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
This trial tests a new drug, SIBP-A18, for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers that have a protein called CLDN18.2.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.